Related Experiment Video

Updated: Sep 16, 2025

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

9.8K

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor

Zongwei Tang1,2, Haichi Song1, Lingyun Pan1

  • 1Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.

Scientific Reports
|July 11, 2025
PubMed

Insights

Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) increase cardiovascular risks. This study found VEGFR-TKIs are linked to thromboembolic events (TEEs), highlighting the need for risk screening during cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are vital targeted cancer therapies.
  • VEGFR-TKIs' anti-angiogenic effects are associated with increased cardiovascular adverse events.
  • Thromboembolic events (TEEs) are a significant concern with VEGFR-TKI treatment.

Purpose of the Study:

  • To comprehensively analyze VEGFR-TKI-related thromboembolic events (TEEs) using real-world data.
  • To identify specific VEGFR-TKIs and event types associated with increased TEE risk.
  • To explore factors influencing the occurrence of TEEs in patients receiving VEGFR-TKIs.

Main Methods:

  • Utilized the FAERS database from drug launch to Q3 2023.
  • Employed disproportionality analyses: reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and Multi-item Gamma Poisson Shrinker.
  • Analyzed 8 VEGFR-TKIs and their associated preferred terms for arterial and venous thromboembolic events.

Main Results:

  • A total of 2688 TEEs were reported, constituting 2.98% of all adverse events linked to VEGFR-TKIs.
  • Lenvatinib showed the strongest TEE signal, with sorafenib, regorafenib, and sunitinib also indicating increased TEE reporting.
  • Identified 17 arterial and 12 venous thromboembolic event terms associated with VEGFR-TKIs.

Conclusions:

  • VEGFR-TKIs are significantly associated with an increased risk of thromboembolic events.
  • Lenvatinib, sorafenib, regorafenib, and sunitinib warrant close monitoring for TEEs.
  • Screening for TEE risk is crucial for patients undergoing VEGFR-TKI cancer therapy.
Keywords:
FAERSPharmacovigilanceThromboembolic eventVascular endothelial growth factor receptor tyrosine kinase inhibitor

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.4K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
996
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
25
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
41
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
35
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
46